Evidence map›Paper›PMID 42211655›Full record

Trial reportFrontiers in cellular and infection microbiology2026

Probiotics alleviate oral microbiota disruptions induced by

Wenjuan Wei, Weiwei Chen, Ruolin Peng, Xiujuan Wang, Zhibin Wang, Zhenyu Zhang

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wenjuan Wei *Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Weiwei Chen *Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Ruolin PengDepartment of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Xiujuan WangDepartment of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Zhibin WangDepartment of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Zhenyu ZhangDepartment of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: A total of 78 Results: Results showed that Conclusion: In conclusion, H. pylori infection disrupts oral microbiota, and 14-day VA therapy induces transient microbial perturbations. Adjunctive probiotics partially mitigate these disruptions, supporting oral microecological stability during eradication therapy, but do not achieve full restoration of microbiota balance to the level of uninfected individuals in the short term. These effects are partial, as complete restoration to uninfected microbiota levels was not achieved within the study follow-up period.Chinese Clinical Trial Registry (ChiCTR2400082446).

Indexed as

AmoxicillinAnti-Bacterial AgentsHelicobacter InfectionsHelicobacter pyloriMicrobiotaMouthProbioticsPyrrolesSulfonamidesAdultBacteriaDNA, BacterialDouble-Blind MethodDrug Therapy, CombinationDysbiosisFemaleAmoxicillinAnti-Bacterial AgentsDNA, BacterialPyrrolesRNA, Ribosomal, 16SSulfonamidesvonoprazaneradicationHelicobacter pylorioral microbiotaprobioticsvonoprazan-amoxicillin dual therapy

Identifiers

PMID42211655
PMCPMC13212275

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.